Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Sandoz Unveils Plan For China Production And Distribution Center

This article was originally published in PharmAsia News

Executive Summary

Novartis Sandoz recently disclosed plans to make its Zhongshan company the China pharmaceutical production base, and will move its current sales center to the city to establish Sandoz China production and distribution center. Set up in Zhongshan in 2007, Novartis Sandoz focuses on pharmaceutical chemicals, capsules, tablets and repackaging of imported medicines. The company's revenue saw more than $40 million in 2008 with its production of eight main types of medicines. Novartis has identified China as the growth engine for its global expansion and top-level corporate executives will visit relevant Chinese government officials by the end of this month. (Click here for more - Chinese Language)

You may also be interested in...



Sandoz Targets RMB 10 Billion China Revenue Within Five Years

During a recent visit to China (PharmaAsia News, Mar. 16, 2009), Sandoz's CEO Jeff George disclosed that global generic drugs will grow annually at 9 percent from 2008 to 2013, while Asia's yearly increase will hit 12 percent. China, spurred by its health care reform, will become the world's second-largest generics market by 2012, with a compound annual growth rate of 14 percent. Eying this opportunity, Sandoz is targeting a revenue of RMB 10 billion for China by 2012, and aims to become among the top three industry manufacturers in the country. The company will accelerate introduction of drugs into China as well as enlarge its operations by M&A or production expansion. (Click here for more - Chinese Language)

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.

UsernamePublicRestriction

Register

SC071054

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel